Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Sep 3;11(9):150.
doi: 10.1038/s41408-021-00544-x.

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Yunxin Chen #  1   2 , Sathish Kumar Gopalakrishnan #  1   3 , Melissa Ooi  4 , Rehena Sultana  5 , Li Hui Lim  1 , Nicholas Grigoropoulos  1   2 , Shin Yeu Ong  1   2 , Mingge Xu  4 ; SGHMM1 Investigators; Wee Joo Chng  4   6 , Yeow Tee Goh  1   2 , Chandramouli Nagarajan  7   8
Collaborators, Affiliations
Clinical Trial

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Yunxin Chen et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Y.C., S.G. and C.N. report grants from Amgen during the conduct of the study. W.J.C. reports grants from Celgene, Janssen, ASLAN. Y.C., W.J.C., C.N. reports personal fees from Amgen, Janssen, BMS. W.J.C. reports personal fees from Abbvie, Novartis, Kyan. C.N. reports personal fees for Abbvie, Astra Zeneca, and Takeda. Other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Survival and Response Rates.
Kaplan–Meier plot of PFS (a), OS (b), and response rates (c). αBest responses were attained in induction among patients who had received at least one dose of the study drug. βResponses among patients who had completed induction and autologous stem cell transplant. δResponses among patients who had completed induction, autologous stem cell transplant, and consolidation. εBest response attained during trial among all patients.
See this image and copyright information in PMC

References

    1. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000-14. Leukemia. 2017;31:1915–21. doi: 10.1038/leu.2016.380. - DOI - PMC - PubMed
    1. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. doi: 10.1200/JCO.2015.61.2267. - DOI - PMC - PubMed
    1. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–9. doi: 10.1182/blood-2012-04-422683. - DOI - PMC - PubMed
    1. Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017;35:2900–10. doi: 10.1200/JCO.2016.69.2517. - DOI - PMC - PubMed
    1. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. doi: 10.1016/S1470-2045(15)00464-7. - DOI - PubMed

Publication types

MeSH terms